CD276 and neoplasm: In hematologic tumors, especially in acute monocytic leukemia and mantle cell lymphoma (MCL), CD276 induces cell-cycle arrest in the G0/G1 phase, and xenograft models show the potent inhibitory role of CD276 in tumor growth.